The UK’s National Institute for Health and Care Excellence (NICE) has recommended Novartis’ Kisqali (ribociclib) as an ...

Artificial intelligence has edged past the pilot phase in clinical development. Once a niche add-on, AI is now helping ...

US rare disease meds developer Sarepta Therapeutics late yesterday announced a strategic restructuring plan designed to ...

UK pharma major GSK has gained US regulatory approval for a new prefilled syringe presentation of its shingles vaccine, ...

Bayer (BAYN: DE) is giving chief executive Bill Anderson more time to deliver on his ambitious efforts to reshape the German ...

Swiss pharma giant Novartis this morning reported second quarter 2025 financial results, showing that net sales were $14.1 ...

Eli Lilly’s (NYSE: LLY) latest acquisition has electrified the biotech world—and sent a clear message that gene editing is no ...

Shares in US healthcare conglomerate Johnson & Johnson rose by 6% during Wednesday morning’s trading after the presentation ...

US biotech Genascence today announced the US Food and Drug Administration (FDA) has granted the Regenerative Medicine Advanced Therapy (RMAT) designation to GNSC-001, a potential first-in-class gene ...

UK pharma major GSK is seeking US approval for Blenrep (belantamab mafodotin) in two multiple myeloma indications.

Canada and USA-based oncology biotech Repare Therapeutics has entered into an exclusive worldwide licensing agreement with ...

The Division of Hepatology and Nutrition of the US Food and Drug Administration (FDA) has lifted the partial clinical hold on ...